Evidence map›Paper›PMID 39042349›Full record

ArticleInternational journal of clinical pharmacy2024

The Medicines Optimisation Innovation Centre: a dedicated centre driving innovation in medicines optimisation-impact and sustainability.

A Hogg, M Scott, G Fleming, C Scullin, R Huey, S Martin, N Goodfellow, C Harrison

Abstract read
In one paragraph

Article in International journal of clinical pharmacy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A HoggMedicines Optimisation Innovation Centre, Antrim, Northern Ireland. Anita.hogg@northerntrust.hscni.net.ORCID http://orcid.org/0000-0002-4369-305X
M ScottMedicines Optimisation Innovation Centre, Antrim, Northern Ireland.ORCID http://orcid.org/0000-0003-4048-0937
G FlemingMedicines Optimisation Innovation Centre, Antrim, Northern Ireland.ORCID http://orcid.org/0000-0001-7321-8092
C ScullinMedicines Optimisation Innovation Centre, Antrim, Northern Ireland.ORCID http://orcid.org/0000-0001-9877-2858
R HueyMedicines Optimisation Innovation Centre, Antrim, Northern Ireland.ORCID http://orcid.org/0000-0002-1500-7593
S MartinMedicines Optimisation Innovation Centre, Antrim, Northern Ireland.ORCID http://orcid.org/0000-0003-1619-958X
N GoodfellowMedicines Optimisation Innovation Centre, Antrim, Northern Ireland.ORCID http://orcid.org/0009-0008-3940-624X
C HarrisonDepartment of Health, Belfast, Northern Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSub-optimal medicines use is a challenge globally, contributing to poorer health outcomes, inefficiencies and waste. The Medicines Optimisation Innovation Centre (MOIC) was established in Northern Ireland by the Department of Health (DH) in 2015 to support implementation of the Medicines Optimisation Quality Framework.

aimTo demonstrate how MOIC informs policy and provides support to commissioners to improve population health and wellbeing.

settingMOIC is a regional centre with multidisciplinary and multi-sector clinical expertise across Health and Social Care and patient representation. DEVELOPMENT: Core funded by DH, MOIC has a robust governance structure and oversight programme board. An annual business plan is agreed with DH. Rigorous processes have been developed for project adoption and working collaboratively with industry. IMPLEMENTATION: MOIC has established partnerships with academia, industry, healthcare and representative organisations across Europe, participating in research and development projects and testing integrated technology solutions. A hosting programme has been established and evaluation and dissemination strategies have been developed. EVALUATION: MOIC has established numerous agreements, partnered in three large EU projects and strengthened networks globally with extensive publications and conference presentations. Informing pathway redesign, sustainability and COVID response, MOIC has also assisted in the development of clinical pharmacy services and antimicrobial stewardship in Europe and Africa. Northern Ireland has been recognised as a 4-star European Active and Healthy Ageing Reference Site and the Integrated Medicines Management model as an example of best practice in Central and Eastern Europe.

conclusionMOIC has demonstrated considerable success and sustainability and is applicable to health systems globally.

Indexed as

Medication SystemsPharmacy Service, HospitalNorthern IrelandClinical pharmacy serviceHealth policyPatient participationPatient safetyPharmacy researchTechnological innovations

Identifiers

PMID39042349
PMCPMC11399211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.